Edison Investment Research - Derma Sciences Inc. Update: Picking up pace

Report

Edison Investment Research

Update: Picking up pace

Derma Sciences delivered a robust Q414 with rebounding sales growth but slowing cost growth. Based on lower overhead and R&D costs, we have tempered our forecast losses 2015-16e and our DCF-based valuation has been raised from $312m to $320m. Accelerated recruitment in the ongoing diabetic foot ulcer trials (DSC127) and improved cost absorption in Advanced Wound Care may lead to profitability as of 2018.

30/03/2015 9 EN

Underlying

Derma Sciences Inc.

See profile

US2498275021 United States

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Other Reports on these Companies

BusinessWire

INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Into Whether the Sale of Derma Sciences, Inc. to Integra LifeSciences Holdings Corporation for $7 Per Share is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)-- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Derma Sciences, Inc. (NASDAQ:DSCI) stock prior to January 10, 2017. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Derma Sciences to Integra LifeSciences Holdings Corporation (NASDAQ: IART). Under the terms of the transaction, Derma Sciences common shareholders will receive $7 per share, while holders of Series A ...

January 27, 2017 January 27, 2017 1 EN

BusinessWire

INVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Derma Sciences, Inc. And Encourages Shareholders To Contact The Firm For Additional Information

STEVENSON, Md.--(BUSINESS WIRE)-- The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Derma Sciences, Inc. (Nasdaq: DSCI) (“Derma Sciences” or the “Company”) relating to the proposed buyout of Derma Sciences by Integra LifeSciences Holdings Corporation. Under the terms of the agreement, Derma Sciences common shareholders will receive $7 per share, while holders of S...

January 18, 2017 January 18, 2017 1 EN

BusinessWire

SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Derma Sciences, Inc. And Encourages Investors To Contact The Firm For Additional Information

January 13, 2017 January 13, 2017 1 EN

Card Factory - Confident on FY25 outlook

Card Factory’s H125 revenue growth demonstrated it is delivering well against its multi-year growth strategy. While profitability was negatively affected by the (mostly) known inflation in operating costs, management is confident Card Factory will achieve its full-year estimates. This is due the momentum in the business and the mismatch in H125 between cost inflation and the efficiency and cost savings that have always been expected to come through in H225.

October 4, 2024 October 4, 2024 1 EN

Sean Conroy

Sean Conroy

Immix Biopharma - US CAR-T trial progresses to dose expansion

Immix Biopharma’s US-based NEXICART-2 trial continues to make steady progress through the clinic, with the company reporting that the trial has advanced to the dose expansion level of 450m cells, after completing the 150m cell cohort. The Phase Ib/II trial is assessing Immix’s lead CAR-T asset NXC-201 as a first-in-class outpatient treatment for relapsed/ refractory amyloid light chain amyloidosis (r/r ALA). We highlight that both chosen doses in NEXICART-2 trial had elicited complete responses in the prior NEXICART-1 trial, which was based in Israel. We view the latest update as an encouragin...

October 4, 2024 October 4, 2024 1 EN

Pedro Fonseca

Pedro Fonseca

Helios Underwriting - Strategic shift from growth to consolidation

Helios Underwriting (Helios) delivered EPS growth of 35% to 7.7p in H124 and reported a net asset value (NAV) of 191p/share. While its combined ratio of 91.6% deteriorated from 88% in H123 and 85% in FY23 due to seasonal impacts on the 2024 year of account (YOA) and stricter reserving for its 2022 YOA, we forecast an improvement to 88.8% for FY24. Helios experienced cost pressures during the period as a result of abandoning its ‘follow-only’ syndicate initiative and the departure of its CEO. We expect a meaningful reduction in costs in FY25, including a saving in stop-loss reinsurance costs as...

October 3, 2024 October 3, 2024 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Update: Picking up pace

INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Into Whether the Sale of Derma Sciences, Inc. to Integra LifeSciences Holdings Corporation for $7 Per Share is Fair to Shareholders

INVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Derma Sciences, Inc. And Encourages Shareholders To Contact The Firm For Additional Information

SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Derma Sciences, Inc. And Encourages Investors To Contact The Firm For Additional Information

Card Factory - Confident on FY25 outlook

Immix Biopharma - US CAR-T trial progresses to dose expansion

Helios Underwriting - Strategic shift from growth to consolidation

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe